Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.25 Average PT from Brokerages

Context Therapeutics Inc. (NASDAQ:CNTX) has been given an average recommendation of “Buy” by the six brokerages that are currently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $5.25.

A number of research firms recently weighed in on CNTX. HC Wainwright dropped their price target on shares of Context Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a research report on Thursday, August 7th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $4.00 price objective (down previously from $4.50) on shares of Context Therapeutics in a research report on Thursday, June 26th.

Context Therapeutics Price Performance

CNTX opened at $0.84 on Tuesday. The company’s 50-day moving average is $0.79 and its 200 day moving average is $0.75. Context Therapeutics has a fifty-two week low of $0.49 and a fifty-two week high of $2.59. The firm has a market capitalization of $74.99 million, a P/E ratio of -2.32 and a beta of 1.91.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). On average, equities research analysts expect that Context Therapeutics will post -0.51 earnings per share for the current year.

Institutional Trading of Context Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new stake in Context Therapeutics in the fourth quarter worth about $29,000. Citadel Advisors LLC bought a new stake in Context Therapeutics in the fourth quarter worth about $31,000. Shay Capital LLC bought a new stake in Context Therapeutics in the fourth quarter worth about $52,000. Millennium Management LLC raised its position in Context Therapeutics by 24.2% in the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company’s stock worth $188,000 after acquiring an additional 34,835 shares during the period. Finally, MPM Bioimpact LLC bought a new stake in Context Therapeutics in the fourth quarter worth about $15,441,000. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.